Chongqing Genrix Biopharmaceutical Co., Ltd. Class ASSE: 688443

Announcement on the Voluntary Disclosure Regarding the Initiation of Phase III Clinical Trial for GR1802 Injection in the Indication of Chronic Spontaneous Urticaria

· Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange
Announcement on the Voluntary Disclosure Regarding the Initiation of Phase III Clinical Trial for GR1802 Injection in the Indication of Chronic Spontaneous Urticaria

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis